ES2732154T3 - Procedimiento de producción de virus envueltos - Google Patents
Procedimiento de producción de virus envueltos Download PDFInfo
- Publication number
- ES2732154T3 ES2732154T3 ES14796166T ES14796166T ES2732154T3 ES 2732154 T3 ES2732154 T3 ES 2732154T3 ES 14796166 T ES14796166 T ES 14796166T ES 14796166 T ES14796166 T ES 14796166T ES 2732154 T3 ES2732154 T3 ES 2732154T3
- Authority
- ES
- Spain
- Prior art keywords
- virus
- lentivirus
- production
- pseudotyped
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims abstract description 36
- 241000700605 Viruses Species 0.000 title claims description 57
- 230000002378 acidificating effect Effects 0.000 claims abstract description 36
- 241000713666 Lentivirus Species 0.000 claims abstract description 31
- 239000002609 medium Substances 0.000 claims description 35
- 239000013612 plasmid Substances 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 23
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108700019146 Transgenes Proteins 0.000 claims description 14
- 241000714177 Murine leukemia virus Species 0.000 claims description 11
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 10
- 238000012546 transfer Methods 0.000 claims description 7
- 241000713826 Avian leukosis virus Species 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 241000710961 Semliki Forest virus Species 0.000 claims description 5
- 241000714474 Rous sarcoma virus Species 0.000 claims description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 4
- 101150047047 gag-pol gene Proteins 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 241000711950 Filoviridae Species 0.000 claims description 3
- 241000713673 Human foamy virus Species 0.000 claims description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims description 3
- 241000712079 Measles morbillivirus Species 0.000 claims description 3
- 108700004030 rev Genes Proteins 0.000 claims description 3
- 101150098213 rev gene Proteins 0.000 claims description 3
- 238000003146 transient transfection Methods 0.000 claims description 3
- 241000712892 Arenaviridae Species 0.000 claims description 2
- 241001203868 Autographa californica Species 0.000 claims description 2
- 241001115402 Ebolavirus Species 0.000 claims description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims description 2
- 241000712003 Human respirovirus 3 Species 0.000 claims description 2
- 241000713326 Jaagsiekte sheep retrovirus Species 0.000 claims description 2
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 2
- 241000725171 Mokola lyssavirus Species 0.000 claims description 2
- 241000526636 Nipah henipavirus Species 0.000 claims description 2
- 241000712464 Orthomyxoviridae Species 0.000 claims description 2
- 241000711504 Paramyxoviridae Species 0.000 claims description 2
- 241000711798 Rabies lyssavirus Species 0.000 claims description 2
- 241000712907 Retroviridae Species 0.000 claims description 2
- 241000711931 Rhabdoviridae Species 0.000 claims description 2
- 241000710942 Ross River virus Species 0.000 claims description 2
- 241000710960 Sindbis virus Species 0.000 claims description 2
- 241000710924 Togaviridae Species 0.000 claims description 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 241000713325 Visna/maedi virus Species 0.000 claims description 2
- 241000710951 Western equine encephalitis virus Species 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims description 2
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 241001485018 Baboon endogenous virus Species 0.000 claims 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 claims 1
- 241000711408 Murine respirovirus Species 0.000 claims 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 50
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 26
- 239000002245 particle Substances 0.000 description 24
- 208000015181 infectious disease Diseases 0.000 description 21
- 230000002458 infectious effect Effects 0.000 description 20
- 239000006228 supernatant Substances 0.000 description 15
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 12
- 230000001177 retroviral effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 7
- 101710177166 Phosphoprotein Proteins 0.000 description 7
- 101710149279 Small delta antigen Proteins 0.000 description 7
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 101710091045 Envelope protein Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 101710188315 Protein X Proteins 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 101000852024 Gibbon ape leukemia virus Envelope glycoprotein Proteins 0.000 description 4
- 201000005505 Measles Diseases 0.000 description 4
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000713730 Equine infectious anemia virus Species 0.000 description 3
- 241000713800 Feline immunodeficiency virus Species 0.000 description 3
- 241001663880 Gammaretrovirus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241001664176 Alpharetrovirus Species 0.000 description 2
- 241001231757 Betaretrovirus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001663879 Deltaretrovirus Species 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000010094 Visna Diseases 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- -1 cell density Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001663878 Epsilonretrovirus Species 0.000 description 1
- 241000035314 Henipavirus Species 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 241000282331 Mustelidae Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241001113283 Respirovirus Species 0.000 description 1
- 241000713656 Simian foamy virus Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000711970 Vesiculovirus Species 0.000 description 1
- 241001533396 Walleye dermal sarcoma virus Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1358909A FR3010720B1 (fr) | 2013-09-16 | 2013-09-16 | Procede de production de virus enveloppes |
| PCT/FR2014/052279 WO2015036713A1 (fr) | 2013-09-16 | 2014-09-12 | Procede de production de virus enveloppes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2732154T3 true ES2732154T3 (es) | 2019-11-20 |
Family
ID=50424334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14796166T Active ES2732154T3 (es) | 2013-09-16 | 2014-09-12 | Procedimiento de producción de virus envueltos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10125352B2 (enExample) |
| EP (1) | EP3047025B1 (enExample) |
| JP (1) | JP6629210B2 (enExample) |
| CN (1) | CN105722984B (enExample) |
| CA (1) | CA2923554C (enExample) |
| DK (1) | DK3047025T3 (enExample) |
| ES (1) | ES2732154T3 (enExample) |
| FR (1) | FR3010720B1 (enExample) |
| RU (1) | RU2016114541A (enExample) |
| SG (1) | SG11201602017YA (enExample) |
| WO (1) | WO2015036713A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| RU2761555C2 (ru) | 2015-10-22 | 2021-12-09 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
| KR20220047635A (ko) | 2019-08-23 | 2022-04-18 | 론자 워커스빌 아이엔씨. | 렌티바이러스 벡터의 생산을 위한 방법 및 작제물 |
| US12365873B2 (en) | 2021-01-28 | 2025-07-22 | Allogene Therapeutics, Inc. | Methods for transducing immune cells |
| WO2023114949A1 (en) * | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005304866B2 (en) | 2004-11-05 | 2010-04-01 | Wellstat Biologics Corporation | Stable and filterable enveloped virus formulations |
| PL2007883T3 (pl) | 2006-04-20 | 2012-07-31 | Wyeth Llc | Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej |
| WO2009153563A1 (en) | 2008-06-18 | 2009-12-23 | Oxford Biomedica (Uk) Limited | Virus purification |
| US10596264B2 (en) * | 2011-06-30 | 2020-03-24 | Genethon | Peptides with viral infection enhancing properties and their use |
| WO2013076309A1 (en) | 2011-11-24 | 2013-05-30 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
-
2013
- 2013-09-16 FR FR1358909A patent/FR3010720B1/fr not_active Expired - Fee Related
-
2014
- 2014-09-12 EP EP14796166.8A patent/EP3047025B1/fr not_active Revoked
- 2014-09-12 US US15/022,049 patent/US10125352B2/en not_active Expired - Fee Related
- 2014-09-12 SG SG11201602017YA patent/SG11201602017YA/en unknown
- 2014-09-12 RU RU2016114541A patent/RU2016114541A/ru not_active Application Discontinuation
- 2014-09-12 CN CN201480050980.4A patent/CN105722984B/zh not_active Expired - Fee Related
- 2014-09-12 WO PCT/FR2014/052279 patent/WO2015036713A1/fr not_active Ceased
- 2014-09-12 CA CA2923554A patent/CA2923554C/fr not_active Expired - Fee Related
- 2014-09-12 JP JP2016542356A patent/JP6629210B2/ja not_active Ceased
- 2014-09-12 ES ES14796166T patent/ES2732154T3/es active Active
- 2014-09-12 DK DK14796166.8T patent/DK3047025T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| DK3047025T3 (da) | 2019-06-24 |
| RU2016114541A (ru) | 2017-10-23 |
| EP3047025B1 (fr) | 2019-04-03 |
| JP2016530890A (ja) | 2016-10-06 |
| FR3010720A1 (fr) | 2015-03-20 |
| CA2923554C (fr) | 2019-10-29 |
| SG11201602017YA (en) | 2016-04-28 |
| US10125352B2 (en) | 2018-11-13 |
| CN105722984B (zh) | 2021-08-13 |
| EP3047025A1 (fr) | 2016-07-27 |
| CN105722984A (zh) | 2016-06-29 |
| JP6629210B2 (ja) | 2020-01-15 |
| FR3010720B1 (fr) | 2017-08-11 |
| WO2015036713A1 (fr) | 2015-03-19 |
| CA2923554A1 (fr) | 2015-03-19 |
| US20160230147A1 (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2753300T3 (es) | Procedimiento de purificación de virus o vectores virales envueltos | |
| Munis | Gene therapy applications of non-human lentiviral vectors | |
| ES2959326T3 (es) | Líneas celulares estables para producción retroviral | |
| ES2423518T3 (es) | Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada | |
| Cronin et al. | Altering the tropism of lentiviral vectors through pseudotyping | |
| CA2413995C (en) | Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity | |
| US10450574B2 (en) | Transient transfection method for retroviral production | |
| US10125352B2 (en) | Method for producing enveloped viruses | |
| ES2726975T3 (es) | Método para la producción de partículas retrovíricas útiles para transducir células eucariotas | |
| WO2024044655A1 (en) | Delivery of heterologous proteins | |
| US20090123494A1 (en) | Momlv-based pseudovirion packaging cell line | |
| CN113166782A (zh) | 增强慢病毒载体产生的方法 | |
| JP2016530890A5 (enExample) | ||
| CN104262477A (zh) | 一种禽CCCH型锌指蛋白chZAP及其应用 | |
| US9840720B2 (en) | Materials and methods relating to packaging cell lines | |
| Olgun et al. | High-titer production of HIV-based lentiviral vectors in roller bottles for gene and cell therapy | |
| Iida et al. | Concept and technology underlying Sendai virus (SeV) vector development | |
| Auste et al. | Concentrating all helper protein functions on a single entity allows rescue of recombinant measles virus by transfection of just two plasmids | |
| JP2013208107A (ja) | レトロウイルスベクターの製造方法 | |
| US20060093590A1 (en) | Pseudotyped retroviruses | |
| CN101979606A (zh) | 一种以腺病毒表达系统产生的人逆转录泡沫病毒载体 | |
| Munis | Envelope glycoproteins of vesiculoviruses: characteristics of antibody interactions and immunogenicity | |
| Urbinati et al. | 467. Lentiviral Vector (LV) Non-Coding Elements That Impart High Titers and Expression to [beta]-Globin (h [beta]) Cassettes | |
| Naumann et al. | 468. Evaluation of Factors Influencing the Production Titers of SIV-Derived Lentiviral Vectors | |
| Costa | New cell lines for the manufacture of lentivirus |